GSK’s new CEO, Luke Miels, plans to boost sales growth and accelerate new medicine development through strategic focus on changing standard of care and bolt-on deals. Shares rose 5.6% to 2,055 pence, the highest in 25 years, backing a sales target of 40 billion pounds by 2031.

Miels aims to rebuild investor trust in GSK’s long-term sales target. Analysts view his approach as steady and credible. The company plans to target deals in the 2-4 billion pound range without major changes to capital allocation strategy, seeking assets to strengthen late-stage pipeline.

GSK expects revenue growth of 3-5% this year, down from 7% in 2025, due to foreign exchange pressure. Core earnings per share were 25.5 pence in Q4 2025, with sales reaching 8.62 billion pounds. New product launches, like asthma drug Exdensur and blood cancer drug Blenrep, are crucial for growth.

Uncertainty looms over GSK’s vaccine business in the U.S. in 2026 due to policy changes. Sales from the vaccine and general medicines units are expected to decline, while the specialty medicines business eyes low-double-digit growth. GSK made a $2.2 billion acquisition of RAPT Therapeutics last month for an experimental food allergy drug.

Read more at Yahoo Finance: GSK eyes sharper, faster drug development as new CEO signals growth plan